| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fentanyl (Recivit®) |
| Formulation | 133 micrograms, 267 micrograms, 400 micrograms, 533 micrograms and 800 micrograms sublingual tablet |
| Reference number | 2479 |
| Indication | Treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain |
| Company | Grunenthal Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 30/01/2014 |